Source: International Congress 2018 – COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Singh (Manchester, United Kingdom), F. Barnhart (Research Triangle Park, United States of America), N. Brealey (Uxbridge, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, United States of America), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Uxbridge, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Mouneimne (Brentford, United Kingdom), R. Wise (Baltimore, United States of America), D. Lipson (Philadelphia, United States of America). FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial. 4383

Member's Comments

No comment yet.

Related content which might interest you: Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPDÔ trial Source: Annual Congress 2011 - COPD management Year: 2011 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Source: Eur Respir J 2014; 44: 1548-1556 Year: 2014 A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Source: ERJ Open Res 2016: 00101-2015 Year: 2016 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials Source: ERJ Open Res, 7 (1) 00816-2020; 10.1183/23120541.00816-2020 Year: 2021 Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials Source: International Congress 2018 – COPD management Year: 2018 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012